Following an infusion of zoledronate acid in low-risk postmenopausal women, fracture risk reduction emerged only 5-10 years later in a placebo-controlled trial. By year 10, those who received a single ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. From 2010 to 2022, 12% of patients in a U.S. database ...

Benefits of infrequent zoledronate acid (Reclast) infusions were seen later rather than sooner for low-risk women, a secondary analysis of a randomized trial indicated. Among 1,054 early ...